The full breakdown is below either way
The safety and effectiveness of Vyvanse for the treatment of obesity have not been established. Risks of Vyvanse for weight loss As Alex Foxman, MD, internist and medical director of Achieve Health and Weight Loss, emphasizes, Vyvanse is not a safe or effective way to lose weight outside of healthcare provider-guided binge eating disorder treatment

Saxenda (Liraglutide) FDA approval: 2014 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Also available as: Victoza (lower dose, approved for Type 2 diabetes) Ozempic (Semaglutide) FDA approval: 2017 for Type 2 diabetes Indicated population: Adults with Type 2 diabetes as adjunct to diet and exercise Not approved for: Weight loss (though commonly prescribed off-label) Wegovy (Semaglutide) FDA approval: 2021 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Adolescents aged 12+ with obesity Same medication as Ozempic: Different dosing and FDA indication Practical Implications The regulatory distinctions matter for: Insurance coverage: Medications are often covered only for their approved indications

If you have an underlying health condition like kidney disease, or if you take medication that interferes with B6 metabolism or absorption (such as oral contraceptives, hypertension drugs like hydralazine, and others), ask your doctor about appropriate supplement dosing
This potential age-related effect may be secondary to a progressive imbalance between ROS production and waning antioxidant defenses during aging, making G6PD-d individuals more susceptible to oxidative stress-induced ASCVD 22